Abstract
Marketing researchers have proposed various conceptual models of ethical decision-making to better clarify the steps in the decision-making process. However, lacking in the literature is comprehensive empirical validation of these models. This manuscript examines the ethical decision-making model proposed by␣Ferrell et al. [1989, Journal of Macromarketing 56(Fall), 55–64] in the context of a real-world marketing situation. This model is a comprehensive synthesis of previously developed models in the literature. The events surrounding the withdrawal from the market of the pain reliever Vioxx, manufactured by Merck & Co., are detailed. The analysis provides insights into the decision-making process faced by Merck executives and sheds light onto the real-world applicability of the conceptual model. Furthermore, this study demonstrates how potential modifications to existing models can be developed by their examination in the context of real world events. It is hoped that this analysis, along with future examinations, aids marketing researchers in developing a better understanding of the ethical decision-making process in a business context.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Berenson, A., G. Harris, B. Meier and A. Pollack: 2004, ‹Despite Warnings, Drug Giant Took Long Path to Vioxx Recall’, The New York Times, p. 1
DiMasi J. A., Hansen R. W., Grabowski H. G.: 2003, “The Price of Innovation: New Estimates of Drug Development Costs”, Journal of Health Economics 22, 151–185
Feder, B. J.: 2004, ‹Vioxx Recall May Bring Flood of Suits to Merck’, The New York Times, p. 2
Ferrell O. C., Gresham L. G.: 1985, “A Contingency Framework for Understanding Ethical Decision-Making in Marketing”, Journal of Marketing 49(Summer), 87–96
Ferrell O. C., Gresham L. G., Fraedrich J.: 1989, “A Synthesis of Ethical Decision Models for Marketing”, Journal of Macromarketing 56(Fall), 55–64
Fritzsche D. J.: 1991, “A Model of Decision-Making Incorporating Ethical Values”, Journal of Business Ethics 10(11), 841–852
Hawthorne, F.: 2003, The Merck Druggernaut: The Inside Story of a Pharmaceutical Giant (John Wiley & Sons, Inc.)
Hunt S. D., Vitell S.: 1986, “A General Theory of Marketing Ethics”, Journal of Macromarketing 6(Spring), 5–16
Jennings, D. and M. Moseley: 2004, The Cleveland Clinic Press Room, http://www.clevelandclinic.org/media/release.asp?Press_Releases_No=236, 30 November 2004
Jones T. M.: 1991, “Ethical Decision-Making by Individuals in Organizations: An Issue-Contingent Model”, Academy of Management Review 16(2), 366–395
Kolata, G.: 2004, ‹A Widely Used Arthritis Drug is Withdrawn’, The New York Times, p. 1
Loe T. W., Ferrell L., Mansfield P.: 2000, “A Review of Empirical Studies Assessing Ethical Decision-Making in Business”, Journal of Business Ethics 25(3), 185–204
Malhotra N. K., Miller G. L.: 1998, “An Integrated Model for Ethical Decisions in Marketing Research”, Journal of Business Ethics 17(3), 263–280
Martinez, B.: 2004, ‹Vioxx Lawsuits May Focus on FDA Warning in 2001’, The Wall Street Journal, p. B1
Martinez, B.: 2005, ‹Merck Documents Shed Light on Vioxx Legal Battles – Records Show Safety Panel Had Early Data Indicating Higher Heart-Problems Risk’, The Wall Street Journal, p. A1
Mathews, A. W. and B. Martinez: 2004, ‹Warning Signs: E-mails Suggest Merck Knew Vioxx’s Dangers at Early Stage – As Heart-Risk Evidence Rose, Officials Played Hardball; Internal Message: ‹Dodge!’ – Company Says ‹Out of Context’, The Wall Street Journal, p. A1
O’Fallon M. J., Butterfield K. D.: 2005, “A Review of The Empirical Ethical Decision-Making Literature: 1996–2003”, Journal of Business Ethics 59, 375–413
Street M., Street V. L.: 2006, “The Effects of Escalating Commitment on Ethical Decision-Making”, Journal of Business Ethics 64, 343–356
Street M. D., Robertson C., Geiger S. W.: 1997, “Ethical Decision-Making: The Effects of Escalation of Commitment”, Journal of Business Ethics 16(11), 1153–1161
Acknowledgments
The author thanks Professor Roger Calantone and Robert Nason for comments on earlier drafts of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Erin Cavusgil is a doctoral student at Michigan State University. She holds a BS in Chemical Engineering from the University of Michigan and an MS in Biomedical Engineering from the University of Minnesota. She spent 3 1/2 years working in the pharmaceutical industry as a chemical engineer. Her main area of research is new product development.
Rights and permissions
About this article
Cite this article
Cavusgil, E. Merck and Vioxx: An Examination of an Ethical Decision-Making Model. J Bus Ethics 76, 451–461 (2007). https://doi.org/10.1007/s10551-006-9302-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10551-006-9302-3